about Lexicon's strategy and operating performance and events or developments that we expect or anticipate will occur in the future, such as projections of our future results of operations or of our financial condition, the potential therapeutic and commercial potential of INPEFA® (sotagliflozin), ZYNQUISTA™(sotagliflozin), LX9211, LX9851 and our other drug programs, the success of our commercialization efforts with respect对于INPEFA和任何其他批准的产品，正在进行和将来的临床试验完成的结果和预期时间，与监管机构有关此类试验的预期时间和结果的预期时间和结果，以及基于此类试验的任何批准，我们的其他研究和开发工作以及我们业务的预期趋势。